Dermata Therapeutics Holdings Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel pharmaceutical products. Its primary focus is on treating medical dermatological conditions with significant market needs. The company's distinctive approach involves leveraging its proprietary platform targeting both inflammatory mechanisms and tissue remodeling, leading to potential therapeutic breakthroughs. Dermata's pipeline includes innovative treatments for a variety of skin disorders, designed to offer improved efficacy over existing solutions. Through strategic partnerships and ongoing clinical research, Dermata aims to address challenging diseases like psoriasis and acne, which impact millions worldwide. Its commitment to innovation positions it as a significant player in the biotechnology industry, potentially transforming the dermatological treatment landscape.
Website3525 Del Mar Heights Rd.
San Diego, CA, 92130
United States
SAN DIEGO, CA / ACCESS Newswire / August 25, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced the official commercial launch of the Tome Foundational Treatment, the first product available for purchase under the Company's Tome skincare brand. The Foundational Treatment is now available for immediate purchase at www.tomeskincare.com, either as a one-time purchase or through a monthly subscription at a discounted price. The commercial launch marks a significant landmark in Dermata's evolution into a direct-to-consumer skincare company and represents the Company's first commercial product under the Tome brand.
- Preorders can be made by visiting www.tomeskincare.com - - Dermata is ready to begin shipping orders on the expected launch date of August 25, 2026 - - Tome Foundational Treatment is a once-weekly topical mask for skin renewal - SAN DIEGO, CA / ...
Investors talking about DRMAW also mention
What share of all stock conversation is about DRMAW?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% new | 0% 0 |
Of the messages about DRMAW that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | — | — | ||
| Bearish | — | — | — | — |
Of the messages about DRMAW that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Analysts | — | — | — | 32.91% | ||
| Announcements | — | — | — | 38.46% | ||
| Controversies | — | — | — | 0% | ||
| Earnings | — | — | — | 0% | ||
| Macro | — | — | — | 28.63% | ||
| Technical Analysis | — | — | — | 0% |
Of the messages about DRMAW, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | — | 0% | 0.87% | ||
| Newcomers | — | — | 100% | 99.13% |